MRNA vs TSLA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MRNA

48.8
AI Score
VS
MRNA Wins

TSLA

44.9
AI Score

Investment Advisor Scores

MRNA

49score
Recommendation
HOLD

TSLA

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA TSLA Winner
Revenue 534.00M 50.62B TSLA
Net Income -2.13B 1.59B TSLA
Net Margin -397.9% 3.1% TSLA
Operating Income -2.20B 1.34B TSLA
ROE -31.4% 1.8% TSLA
ROA -19.4% 1.1% TSLA
Total Assets 10.96B 148.52B TSLA
Cash 1.72B 15.22B TSLA
Debt/Equity 0.09 0.09 TSLA
Current Ratio 2.29 1.94 MRNA
Free Cash Flow -1.25B 352.00M TSLA

Relative Price Performance (Last 90 Days)

MRNA 1M: -23.7% · 3M: +20.3% TSLA 1M: -19.2% · 3M: -20.2%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $58.39

TSLA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 42

RSI (14): 41.6 · Price: $328.60

Fundamentals Snapshot

Metric MRNA TSLA
Market Cap
Forward P/E -11.0 148.1
Trailing P/E 293.1
Revenue (TTM)
Revenue Growth 0.0% 0.3%
Gross Margin -0.7% 0.2%
Operating Margin -5.6% 0.0%
EPS -7.88 1.09
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.